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Abstract
Background: The underlying reasons for differences between clinical practice and systematically
developed guidelines vary from one clinical problem to another. It is therefore logical to tailor
strategies to support the implementation of guidelines to address identified barriers to change. The
objective of this trial is to evaluate the effects of a tailored intervention to support the
implementation of systematically developed guidelines for the use of antihypertensive and
cholesterol-lowering drugs for the primary prevention of cardiovascular disease.
Methods/Design: Unblinded, cluster-randomised trial. 150 general practices will be recruited
from two geographical areas in Norway, and randomised to the intervention or control group
(passive dissemination of guidelines). Outcomes will be measured for all eligible patients seen in the
participating practices during one year after the intervention. A multifaceted intervention has been
tailored to address identified barriers to change. Key components are an educational outreach visit
with audit and feedback, and computerised reminders. Pharmacists will conduct the visits. During
the outreach visit the main recommendations will be presented and software will be installed that
links to the electronic medical record systems used in the participating practices. The software will
perform an audit that will be fed back during the visit, present pop-up reminders for patients with
high blood pressure or cholesterol, and provide a cardiovascular risk calculator and patient
education material. The main outcomes are the proportions of 1) first time prescriptions for
hypertension where thiazides are not prescribed, 2) patients not assessed for cardiovascular risk
before prescribing antihypertensive or cholesterol-lowering drugs, and 3) patients treated for
hypertension or high cholesterol for three months or more who have not achieved recommended
treatment goals.
Background
Hypertension and hypercholesterolaemia are common
problems in general practice and have important conse-
quences for patients and the use of healthcare resources.
In Norway the cost of prescription drugs for hypertension
and hypercholesterolaemia accounts for 18% of the total
public expenditure on drugs [1]. Cardiovascular disease is
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a common cause of death and an important cause of mor-
bidity in Norway.
Appropriate use of antihypertensive and cholesterol-low-
ering drugs for the primary prevention of cardiovascular
disease can have important benefits, whereas inappropri-
ate prescribing entails substantial costs, as well as undesir-
able consequences for patients.
There is high quality evidence from well-designed ran-
domised trials of the effects of antihypertensive and cho-
lesterol-lowering drugs for the primary prevention of
cardiovascular disease [2,3]. There are also a number of
clinical practice guidelines, often with conflicting recom-
mendations, e.g on the choice of drug or threshold to start
treatment [4]. Based on a review of previous guidelines
and the underlying evidence, we developed guidelines for
prescribing anthihypertensive and cholesterol-lowering
drugs for the primary prevention of cardiovascular disease
in Norwegian general practice [5–7].
There is potential for improvement for three key recom-
mendations: cardiovascular risk is commonly not meas-
ured before starting treatment [8], thiazides are under-
utilised when initiating treatment for hypertension [1],
and treatment goals are frequently not achieved for both
blood pressure and cholesterol [9,10]. We have therefore
developed an intervention aimed at supporting the imple-
mentation of these three recommendations and planned
a trial to assess the effectiveness and costs of this
intervention.
The results of evaluations of interventions to improve
clinical practice vary and large effects are not common
[11,12]. As with any behaviour, professional behaviour is
difficult to change. Several strategies have been used.
Some of them, like passive dissemination of clinical prac-
tice guidelines, have little or no effect on practice [12,13].
Other, more active strategies, like educational outreach
visits [14] and multifaceted interventions [11], are more
effective, but require more resources [11]. The underlying
reasons for differences between clinical practice and sys-
tematically developed guidelines vary from one clinical
problem to another and from one clinician to another
[15,16]. It is therefore logical to tailor strategies to support
the implementation of guidelines to address identified
barriers to change [15]. However, the effects of such inter-
ventions remain uncertain [16,17]. They should be rigor-
ously evaluated before they are widely used. Because the
effects are expected to be moderate, at best, and biases,
particularly non-equivalent comparison groups, can easi-
ly distort the results of evaluations, cluster-randomised
trials (in which healthcare professionals or groups of pro-
fessionals, rather than patients are randomised) are more
likely to provide valid results than other research designs,
such as controlled before-after or time-series studies [18].
Objectives
The primary objective of this trial is to evaluate the effects
of a tailored intervention to support the implementation
of guidelines by Norwegian general practitioners for the
use of antihypertensive and cholesterol-lowering drugs for
the primary prevention of cardiovascular disease. Our hy-
pothesis is that the tailored intervention will be more ef-
fective than passive dissemination of the guidelines at
reducing the proportions of first time prescriptions for hy-
pertension where thiazides are not prescribed, patients
not assessed for cardiovascular risk before prescribing an-
tihypertensive or cholesterol-lowering drugs, and patients
treated for hypertension or high cholesterol for three
months or more who have not achieved recommended
treatment goals.
Secondary objectives are to estimate the use of resources
associated with the intervention and the effects of the in-
tervention on other relevant outcomes. We anticipate that
passive dissemination of guidelines, which is unavoidable
for published guidelines, will have little effect on the out-
comes of interest [11–13] and is therefore an appropriate
control-intervention.
A process evaluation, to understand the effects or lack of
effects of the intervention, and an economic analysis, if
the intervention is effective, are described in separate
protocols.
Methods
Design
The main hypotheses will be tested using a cluster-ran-
domised controlled trial comparing outcomes between
the intervention and control groups at follow up. General
practices will be randomised to receive a tailored interven-
tion to support implementing the guidelines or to a con-
trol group (see Figure 1). Data will be collected for all
eligible patients from participating practices for one year
after the outreach visit. For the control group data will be
collected for one year after publication of the guidelines in
the Journal of the Norwegian Medical Association.
Participants
All general practices in or near to Oslo or Tromsø in Nor-
way that use one of two electronic medical record systems
(WinMed or ProfDoc Vision) are eligible for the trial.
Over 80% of Norwegian general practices use one of three
electronic medical record systems, and these are used rou-
tinely during consultations. The two restrictions are prag-
matic. 1) The computer software that will be used does
not yet function with the third electronic medical record
system. 2) We have recruited four pharmacists to carry outBMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/5
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Figure 1
Flow of practices through trial
388 eligible practices invited to 
participate
Practices that do 
not consent to 
participate
Anticipated loss to 
follow-up due to drop-
outs or technical 
problems is estimated 
to be roughly 10% (8 
practices)
Anticipated loss to 
follow-up due to drop-
outs or technical 
problems is estimated 
to be roughly 10% (8 
practices)
67 practices in the
tailored intervention 
Intervention beginning 
between May and 
December 2002 and lasting 
for one year
75 practices in the
tailored intervention 
75 practices in 
the control group
67 practices in 
the control group
Clinical practice guidelines 
published in Journal of the 
Norwegian Medical Association in 
September 2002
150 practices that consent to 
participate
Data collected from 
electronic medical records 
for one year after outreach 
visits 
(May to December 2003)
Data collected from 
electronic medical records 
for one year after 
publication of guidelines 
(September 2003)
RandomisationBMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/5
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the outreach visits. Three of them live in the Oslo area and
one near to Tromsø. We have chosen to recruit practices in
the corresponding geographical areas. There are 388 gen-
eral practices that meet these inclusion criteria. All of these
practices will be invited to participate.
Intervention
We developed our intervention through a process of iden-
tifying barriers to implementation of the recommenda-
tions and subsequently coming up with suggestions of
measures that may facilitate change by specifically ad-
dressing the barriers ("tailoring"). This was mainly done
through active reflection and discussions in a group of
three physicians with experience from general practice
(including two of the authors, AF and ADO). In order to
structure the reflection we used a worksheet designed to
facilitate the discussion by listing possible factors that
may act as barriers within the practice environment, with-
in the professional environment, and related to physi-
cians' knowledge, skills and attitudes [19]. We also took
into account information gathered from a survey of gener-
al practitioners, experience from our own research, and
from discussion with physicians during pilot testing of the
intervention.
In order to identify previously executed trials of interven-
tions targeted at the management of hypertension and/or
elevated cholesterol in general practice, the trial register of
the Cochrane Group of Effective Practice and Organisa-
tion of Care (EPOC) was searched in July 2001 (See Addi-
tional File 1: Appendix) [20].
Table 1 describes the various elements of our
intervention.
The practical implementation of the intervention will be
initiated through an educational outreach visit carried out
by pharmacists recruited specifically for this purpose. No
specific qualifications will be demanded, and the pharma-
cists will be given the necessary training during two weeks
in our department. This training will cover basic research
methods, the content of the clinical practice guidelines,
and two days dedicated to communication techniques.
During the outreach visit the main elements of the guide-
line will be presented, with special emphasis on risk esti-
mation, choice of first-line drugs, and treatment goals. A
printed copy of the guideline and a one-page version will
be given to the physicians, including a chart to aid the es-
timation of cardiovascular risk.
During the visit a software package will be installed. This
enables us to extract data and immediately, during the vis-
it, present the physicians with data on their performance
concerning risk estimation, choice of antihypertensive
drugs and achievement of treatment goals ("audit and
Table 1: Elements of the tailored intervention
Educational outreach visit
• Presentation focusing on three main messages:
1. Relevance of risk estimation and how to do it, including strategies on how to communicate 
information about risk to patients.
2. Information on evidence in support of effect and the unjustified fear of adverse effects regarding 
thiazides, pointing at the consensus that exists among guidelines. Attention also directed to the 
importance of clinically relevant endpoints when studies are quoted.
3. Clear recommendations justified by referring to high degree of consensus among guidelines.
• Guidelines handed out, directing attention to the authors (opinion leaders)
Audit & feed-back at outreach visit
• To what extent treatment goals are achieved.
• Drug-choice profile on antihypertensives
• Level of risk among patients on treatment, compared to a sample (men 40–65 years) not on treat-
ment
Computerised reminders
• Risk assessment
• First-choice antihypertensive drugs
• Treatment goals
Risk assessment tools as charts and in electronic format
Patient-information material
• The relationship between single risk factors and global risk
• Thiazides and beta-blockers.
• Treatment goals
Follow-up
• Telephone call to the practice within 1–3 days to check that software has not led to any difficulties
• Short telephone call to each physician after 1–3 monthsBMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/5
Page 5 of 8
(page number not for citation purposes)
feed-back"). The software package also includes compu-
terized reminders using "pop-ups" on the computer
screen (see Figure 2). These are triggered at the patient's
first visit following a recording of an elevated blood pres-
sure- or cholesterol-level (blood pressure > 140/90 mm
Hg or total-cholesterol > 5 mmol/L or LDL-cholesterol > 3
mmol/L). The physician can easily close the "pop-ups"
each time they appear. We will not record how often this
is done.
If the patient has not been prescribed blood-pressure- or
cholesterol-lowering drugs the physician is reminded of
the recommendation to carry out cardiovascular risk as-
sessment and is offered to start a computerized risk assess-
ment tool (SmartHeart). Recommendations on choice of
drugs are also given and the physician is also given the op-
tion of printing out patient information material.
If the patient has been prescribed blood-pressure- or cho-
lesterol-lowering drugs, the "pop-up" will remind the
physician of recommended treatment goals and ask if the
physician would like to print out patient information
material.
Figure 2
Example of pop-up on physician's computer screen. The pop-ups provide various reminders to the physician related to 
specific patients. For example, if the most recent blood pressure recorded within the last six months is above 140/90 mm Hg, 
the physician will be asked if antihypertensive therapy is being considered when the patient's medical record is opened. If the 
physician responds "Yes" the pop-up in the figure appears, which reminds the physician that thiazides are first-choice drug for 
most cases of uncomplicated hypertension and asks if he/she would like to prescribe a thiazide. If the response is "Yes" the 
next pop-up provides brand names of available thiazide-drugs.BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/5
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At the outreach visit a follow-up phone-call with each in-
dividual physician will be scheduled for 1–3 months after
the initial visit and will focus on what questions, prob-
lems or concerns the physicians may have.
The pharmacists will complete a questionnaire after each
outreach visit, enquiring about technical problems, physi-
cian-attitudes, and the pharmacist's own impression of
the session.
One to two days after the visit a member of the research
team will call the office to confirm that they are not expe-
riencing problems as a result of our visit.
Outcome measures
We have chosen three main outcome measures, all aimed
at physician-behaviour regarding the pharmacological
management of primary prevention of cardiovascular dis-
ease for the 12 months following the outreach visit. Pa-
tients with a recorded cardiovascular diagnosis are
excluded, with the exception of the third main outcome.
Because antihypertensive drugs are also being prescribed
for the treatment of thyrotoxicosis and migraine, we have
excluded data from patients where these diagnoses are re-
corded. Patients are considered as previously untreated if
they have hypertension (blood pressure > 140/90 mmHg)
and/or hypercholesterolaemia (total-cholesterol > 5
mmol/L or LDL-cholesterol > 3 mmol/L) and no prescrip-
tion for the corresponding medication has been recorded
for 24 months preceding the outreach visit.
Main outcomes
• The proportion of prescriptions of other antihyperten-
sives than thiazides to patients who are being prescribed
antihypertensive drugs for the first time. (Measurement:
data drawn from the practice medical record system.)
• The proportion of patients where the level of cardiovas-
cular risk has not been estimated among all those started
on antihypertensive or cholesterol lowering treatment.
(Method: Physicians are given the names of the patients
they have put on treatment and are asked if the cardiovas-
cular risk has been evaluated, and if so: what the level
was.)
• Proportion of patients with a recorded level of cholester-
ol (total or LDL) or blood pressure not satisfying the spec-
ified treatment goals, among all patients on the
corresponding treatment for at least three months. For
cholesterol we have decided to also include patients on
secondary prevention therapy since the treatment goals
are similar. (Measurement: data drawn from the practice
medical record system.)
We will also investigate the following outcomes
• The proportion of patients reporting that they were not
involved in the decision-making process before drug treat-
ment for hypertension and/or elevated cholesterol was
started. (Measurement: questionnaire sent to patients by
their physician, and returned anonymously to the re-
search team.)
• Level of risk among patients started on treatment.
(Measurement: Data drawn from the practice medical
record system, and entered into a version of the Framing-
ham-equation [21].)
• Proportion of patients with risk under 20% receiving
treatment among those receiving treatment. (Measure-
ment: Data drawn for the practice medical record system,
and entered into a version of the Framingham-equation.)
• Level of risk among patients not started on treatment
where blood pressure and cholesterol level has been re-
corded. (Measurement: Data on drawn from the practice
medical record system, and entered into a version of the
Framingham-equation.)
• Proportion of prescriptions of other antihypertensives
than thiazides and beta-blockers to patients who are being
prescribed antihypertensive drugs for the first time.
(Measurement: data drawn from the practice medical
record system.)
• Proportion of angiotensin-II-receptor blockers and/or
alpha-blockers among prescripions of antihypertensives
to patients who are being prescribed antihypertensive
drugs for the first time. (Measurement: data drawn from
the practice medical record system.)
• Subgroup-analysis for patients with diabetes: Propor-
tion of patients with a recorded level of cholesterol (total
or LDL) or hypertension not satisfying the specified treat-
ment goals, among all patients on the corresponding
treatment. For cholesterol we have decided to also include
patients on secondary prevention therapy since the treat-
ment goals are similar. (Measurement: data drawn from
the practice medical record system.)
• Proportion of patients not reaching the specified treat-
ment goal for blood pressure (Measurement: data drawn
from the practice medical record system.)
• Proportion of patients not reaching the specified treat-
ment goal for cholesterol (Measurement: data drawn from
the practice medical record system.)BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/5
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Economic analysis
We will record parameters that describe costs related to
our intervention:
• Salary-costs for pharmacists
• Time spent arranging for appointments at the doctors'
practices
• Travel expenses in connection with each outreach visit
• Amount of physician-time spent at each visit
• Materials
• Training
• Other direct expenses related to the implementation of
the intervention
The economic analysis, which will only be conducted if
the intervention is effective, will be described in a separate
protocol.
Pilot study
The intervention has been tested on a small group of gen-
eral practitioners. The first 10 practices that receive the in-
tervention will be excluded from the study and defined as
a pilot-group if major practical problems arise.
Recruitment and randomisation
Block-randomisation was done within each geographical
stratum: the Oslo-area and Northern Norway. The size of
the blocks varied randomly between 2, 4 and 6. A col-
league not directly involved in our research project gener-
ated the allocation-list using software from http://
www.randomisation.com. We gave her ID-numbers repre-
senting each recruited practice, and she informed us
whether the practice was allocated to the intervention- or
control-group.
Baseline data
Baseline data (12 months before the intervention) will be
collected for all outcomes on prescribing and measure-
ments of blood pressure or cholesterol.
Ethics
The doctors who are invited to participate in the study will
be given information about the objectives of the study
and the practical impact it may have on their practice.
They will be told that they will be randomised to an exper-
imental or control group. We will obtain written consent
from all practices. The aim of this study is to improve
quality of care and thus should not imply any risk for the
patients affected by the study. It is difficult to imagine that
our intervention could worsen the quality of care. We
have presented the project for the Regional Committee of
Research Ethics and they did not consider it necessary to
submit the protocol for approval.
The Norwegian Data Inspectorate has approved the han-
dling of data. In accordance with regulations we have as-
sessed the risk of misuse of the data we will be collecting.
The risk is minimal due to the fact that the data are linked
to a reference number that can only be linked to the spe-
cific patient by accessing the computer-system at the prac-
tice of the patient's physician using a program developed
for this task.
Sample size and statistics
In order to demonstrate a 25% relative reduction, with a
power of 80% and a statistical significance level of 5%, in
outcome measures between the control and intervention
groups, we estimated a need for a sample of almost 140
practices in total (Cluster Randomisation Sample Size
Calculator ver 1.0.2, Health Services Research Unit, Aber-
deen University). We assumed that none of the main out-
comes would be less than 50% in the control group and
that the average number of patients included per practice
would be around 10 per outcome measure (three patients
per physician, and three physicians per practice). This was
based on sales figures of anti-hypertensive drugs [1], a sur-
vey on the usage of risk assessment tools [8], published
figures on achievement of treatment goals [9,10], esti-
mates on the prevalence of hypertension-treatment (9%
of those aged over 25) [22], and data we previously had
collected from a group of practices. The sample size also
takes into account the need to adjust for intracluster cor-
relation, which is a consequence of randomising at one
level (clinical practices) and analysing at another (pa-
tients). The adjusting factor was conservatively estimated
to be 0.2, based on data from a previous study [17].
We will carry out post-test comparisons between the inter-
vention- and control-group using cluster-adjusted chi-
square and T-tests. Analysis of covariance may be used to
adjust for imbalance of baseline levels between the inter-
vention- and control-groups [23].
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